PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-4.83%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-4.74%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-11.58%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-25.27%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-11.81%
Negative net income growth while 3391.T stands at 4.16%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-11.81%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-11.81%
Negative diluted EPS growth while 3391.T is at 0.03%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-0.00%
Share reduction while 3391.T is at 0.24%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.00%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
44.88%
10Y CAGR of 44.88% while 3391.T is zero. Bruce Berkowitz would see if incremental growth can widen into a significant edge.
-7.45%
Negative 5Y CAGR while 3391.T stands at 76.24%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
38.84%
3Y revenue/share CAGR at 50-75% of 3391.T's 56.23%. Martin Whitman would question if the firm lags behind competitor innovations.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
194.01%
10Y net income/share CAGR of 194.01% while 3391.T is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
16.46%
Below 50% of 3391.T's 221.26%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
59.57%
3Y net income/share CAGR 50-75% of 3391.T's 94.22%. Martin Whitman might see a lagging edge in short-term profitability vs. the competitor.
131.98%
Equity/share CAGR of 131.98% while 3391.T is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
27.65%
Below 50% of 3391.T's 91.90%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
68.35%
3Y equity/share CAGR 1.25-1.5x 3391.T's 45.67%. Bruce Berkowitz confirms timely buybacks or margin improvements drive stronger near-term equity growth.
No Data
No Data available this quarter, please select a different quarter.
-2.78%
Negative 5Y dividend/share CAGR while 3391.T stands at 188.00%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
-30.00%
Negative near-term dividend growth while 3391.T invests at 66.15%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
-12.20%
Firm’s AR is declining while 3391.T shows 0.92%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
6.37%
Inventory growth well above 3391.T's 3.66%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
1.87%
Asset growth at 75-90% of 3391.T's 2.35%. Bill Ackman suggests reviewing opportunities to match or surpass the competitor's asset expansion if profitable.
5.11%
1.25-1.5x 3391.T's 4.17%. Bruce Berkowitz sees if the firm's capital management strategies surpass the competitor's approach.
-6.73%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
No Data
No Data available this quarter, please select a different quarter.
2.77%
SG&A growth well above 3391.T's 1.26%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.